BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 33218938)

  • 21. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
    Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
    Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
    Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
    World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
    Front Endocrinol (Lausanne); 2021; 12():646793. PubMed ID: 34122331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of key genes and miRNAs markers of papillary thyroid cancer.
    Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
    Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.
    Hosseinkhan N; Honardoost M; Blighe K; Moore CBT; Khamseh ME
    J Endocrinol Invest; 2020 Jul; 43(7):911-923. PubMed ID: 31965517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
    Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
    J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
    Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
    OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis.
    Nicolson NG; Brown TC; Korah R; Carling T
    Surgery; 2020 Jan; 167(1):66-72. PubMed ID: 31439400
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Wen J; Lin B; Lin L; Chen Y; Wang O
    Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma.
    Wang Z; Ji X; Zhang Y; Yang F; Su H; Zhang H; Li Z; Zhang W; Sun W
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
    Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
    Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Set of Markers Related to Viral Infection Has a Sex-sensitive Prognostic Value in Papillary Thyroid Carcinoma.
    Wan D; Yang X; Li G; Du Y; Cao J; Gao Y; Shu Z; Zhou Y; Wei X; Guo R; Zhang R; Zhang G
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2334-e2346. PubMed ID: 33395461
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Xiao Y; Zhang H; Du G; Meng X; Wu T; Zhou Q; Wang Y; Tan B
    Technol Cancer Res Treat; 2020; 19():1533033820970684. PubMed ID: 33176601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Key candidate genes associated with BRAF
    Yu X; Zhong P; Han Y; Huang Q; Wang J; Jia C; Lv Z
    J Cell Physiol; 2019 Dec; 234(12):23369-23378. PubMed ID: 31161615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
    Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.
    Gu Y; Feng C; Liu T; Zhang B; Yang L
    PLoS One; 2018; 13(12):e0209338. PubMed ID: 30576338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bromodomain 4 is a potent prognostic marker associated with immune cell infiltration in breast cancer.
    Zhong L; Yang Z; Lei D; Li L; Song S; Cao D; Liu Y
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):169-182. PubMed ID: 32799413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
    Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
    BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer.
    Lin P; Guo YN; Shi L; Li XJ; Yang H; He Y; Li Q; Dang YW; Wei KL; Chen G
    Aging (Albany NY); 2019 Jan; 11(2):480-500. PubMed ID: 30661062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.